Aurora Cannabis earnings show big growth in pot sales, but worrisome profit trend

This post was originally published on this site

Aurora Cannabis Inc. nearly quadrupled its revenue and claimed a strong market share in an earnings report Monday that detailed the first quarter of legal recreational-pot sales in Canada, but also showed off large losses and a shrinking margin.

Aurora ACB, -5.53% ACB, -4.52%  disclosed losses of C$237.8 million on net revenue of C$54.2 million, after reporting a profit of C$7.7 million on sales of C$11.7 million a year ago. Large losses were expected due to a decline in marijuana-related equities last quarter, as Aurora has invested heavily in other companies in the industry and must track their performance as part of its earnings — Aurora said that those adjustments accounted for about C$190 million of its losses.

The results reflect the launch of legal marijuana sales in Canada, the first industrialized nation to allow recreational-pot sales nationwide. Aurora claimed a large market share for Canada in the launch quarter, with $21.6 million of its revenue coming from its home country.

Marijuana IPOs in 2019: These companies could be the next hot pot stocks

“Based on available data released by Health Canada for the Q2 2019 period, Aurora accounted for approximately 20% of all consumer sales across the country,” Aurora said in its announcement.

Aurora announced in January that it expected revenue of C$50 million to C$55 million, net of excise taxes. Not enough analysts cover the company for a worthy consensus estimate. Aurora shares bounced around in late trading, but mostly showed small gains of less than 2% after its numbers were released.

Aurora’s shrinking margin may be more worrisome than the stock-influenced quarterly loss. Aurora said its gross margin on cannabis sales shrank to 54% from 70% in the prior quarter and 63% in the year-ago quarter. Aurora stuck by its goal of showing adjusted profit in the fiscal fourth quarter, however, and said that the margin change should be temporary.

“The decrease [in gross margin] was primarily due to a lower average selling price per gram of dried cannabis, the impact of excise taxes on medical cannabis net revenues, and a temporarily lower proportion of cannabis oil sales in the company’s sales mix ratio. Also impacting gross margin were increased packaging requirements under the Cannabis Act and one-time ramp-up and optimization costs as our Sky facility was brought up to full production,” Aurora said in its announcement, referencing a marijuana-grow facility. “The company anticipates that the launch of new derivative product lines, once allowed under Health Canada regulations, will contribute to improving margins.”

Marijuana stocks to watch: Aurora Cannabis investments may be more valuable than its pot

Previously, Aurora earnings were boosted by its wide-ranging investments in other marijuana-related companies, but a downturn in pot stocks at the end of last year was expected to hit the company’s bottom line in this report. That hasn’t stopped Aurora from continuing to invest, including acquiring a medical-marijuana distributor in Mexico and investing in High Tide Inc. late last year, as well as announcing the purchase of one of the last independent members of the so-called “blessed eight” in January.

The company announced Monday morning that it had shipped its first cannabis oil to the United Kingdom. Aurora previously said that it is shipping marijuana to more than 20 countries.

Pot stocks were largely lower Monday ahead of Aurora’s earnings release. Canopy Growth Corp. CGC, -5.56% WEED, -5.06%  stock fell 5.6%, Cronos Group Inc. CRON, -0.56% CRON, -0.65%  stock fell 0.6%, and Tilray Inc. TLRY, -4.82%  shares dropped 4.8%. The ETFMG Alternative Harvest ETF MJ, -2.33%  , which tracks a basket of pot stocks, fell 2.3%, and the Horizons Marijuana Life Sciences Index ETF HMMJ, -2.95%  fell 3%.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.